Tweet
Virology. 2016 Oct 14;500:1-10. doi: 10.1016/j.virol.2016.10.008. [Epub ahead of print]
Canine influenza viruses with modified NS1 proteins for the development of live-attenuated vaccines.
Nogales A1, Huang K2, Chauch? C3, DeDiego ML4, Murcia PR3, Parrish CR2, Mart?nez-Sobrido L5.
Author information
Abstract
Canine Influenza Virus (CIV) H3N8 is the causative agent of canine influenza, a common and contagious respiratory disease of dogs. Currently, only inactivated influenza vaccines (IIVs) are available for the prevention of CIV H3N8. However, live-attenuated influenza vaccines (LAIVs) are known to provide better immunogenicity and protection efficacy than IIVs. Influenza NS1 is a virulence factor that offers an attractive target for the preparation of attenuated viruses as LAIVs. Here we generated recombinant H3N8 CIVs containing truncated or a deleted NS1 protein to test their potential as LAIVs. All recombinant viruses were attenuated in mice and showed reduced replication in cultured canine tracheal explants, but were able to confer complete protection against challenge with wild-type CIV H3N8 after a single intranasal immunization. Immunogenicity and protection efficacy was better than that observed with an IIV. This is the first description of a LAIV for the prevention of H3N8 CIV in dogs.
Copyright ? 2016 The Authors. Published by Elsevier Inc. All rights reserved.
KEYWORDS:
Canine influenza virus; Canine tracheal explant; Inactivated influenza vaccines; Influenza A virus; Live-attenuated influenza vaccines; NS1 deficient influenza viruses; Non-structural protein 1; Reverse genetics
PMID: 27750071 DOI: 10.1016/j.virol.2016.10.008
[PubMed - as supplied by publisher] Free full text
Canine influenza viruses with modified NS1 proteins for the development of live-attenuated vaccines.
Nogales A1, Huang K2, Chauch? C3, DeDiego ML4, Murcia PR3, Parrish CR2, Mart?nez-Sobrido L5.
Author information
Abstract
Canine Influenza Virus (CIV) H3N8 is the causative agent of canine influenza, a common and contagious respiratory disease of dogs. Currently, only inactivated influenza vaccines (IIVs) are available for the prevention of CIV H3N8. However, live-attenuated influenza vaccines (LAIVs) are known to provide better immunogenicity and protection efficacy than IIVs. Influenza NS1 is a virulence factor that offers an attractive target for the preparation of attenuated viruses as LAIVs. Here we generated recombinant H3N8 CIVs containing truncated or a deleted NS1 protein to test their potential as LAIVs. All recombinant viruses were attenuated in mice and showed reduced replication in cultured canine tracheal explants, but were able to confer complete protection against challenge with wild-type CIV H3N8 after a single intranasal immunization. Immunogenicity and protection efficacy was better than that observed with an IIV. This is the first description of a LAIV for the prevention of H3N8 CIV in dogs.
Copyright ? 2016 The Authors. Published by Elsevier Inc. All rights reserved.
KEYWORDS:
Canine influenza virus; Canine tracheal explant; Inactivated influenza vaccines; Influenza A virus; Live-attenuated influenza vaccines; NS1 deficient influenza viruses; Non-structural protein 1; Reverse genetics
PMID: 27750071 DOI: 10.1016/j.virol.2016.10.008
[PubMed - as supplied by publisher] Free full text